TRIM28: A Novel E3 Ubiquitin Ligase Guarding the Heart Against Ischemia/Reperfusion-Induced Ferroptosis
Posted inCardiology Internal Medicine news

TRIM28: A Novel E3 Ubiquitin Ligase Guarding the Heart Against Ischemia/Reperfusion-Induced Ferroptosis

New research identifies TRIM28 as a critical E3 ubiquitin ligase that degrades IRP2, thereby suppressing iron uptake and preventing myocardial ferroptosis during ischemia/reperfusion injury. This pathway, activated by p55γ and the drug perhexiline, offers a promising therapeutic target for patients with ischemic heart disease.
Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma
Posted inGastroenterology news Oncology

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma

A breakthrough study reveals that the balance between FYN and LCK kinases acts as a metabolic switch in hepatocellular carcinoma. By modulating this axis through low-dose LCK inhibition, researchers successfully preserved T-cell stemness and mitochondrial health, significantly enhancing the efficacy of immune checkpoint blockade.
Distinctive Endocrine Profiles and Hyperphagia in Rare Genetic Neurodevelopmental Disorders: Beyond the Prader-Willi Paradigm
Posted inClinical Updates Diabetes & Endocrinology Neurology news

Distinctive Endocrine Profiles and Hyperphagia in Rare Genetic Neurodevelopmental Disorders: Beyond the Prader-Willi Paradigm

This review synthesizes findings from a national multicenter study identifying that hyperghrelinemia is a specific biomarker for Prader-Willi Syndrome, whereas other rare neurodevelopmental disorders exhibit normal ghrelin levels despite severe hyperphagia and significant caregiver burden.
Targeting CXCR6: A New Therapeutic Frontier in Immune Checkpoint Inhibitor-Induced Myocarditis
Posted inCardiology news Oncology

Targeting CXCR6: A New Therapeutic Frontier in Immune Checkpoint Inhibitor-Induced Myocarditis

This study identifies CXCR6+ T cells as the primary drivers of immune checkpoint inhibitor-induced myocarditis, especially with anti-LAG-3/PD-1 combinations. Researchers demonstrate that targeting the CXCR6-CXCL16 axis can reduce cardiac inflammation and mortality, offering a promising strategy for managing this life-threatening complication.